Empagliflozin 10mg Tablets
Empagliflozin 10mg
Tablet · Prescription medication
JW Pharmaceutical Co., Ltd.
MFDS item code 202102044 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in adults with type 2 diabetes. It can be administered as monotherapy, and in cases where blood sugar control is difficult, it may be used in combination with metformin, pioglitazone, sulfonylureas, insulins, or the DPP-4 inhibitor linagliptin. Special care should be taken when used in patients with type 2 diabetes confirmed to have cardiovascular disease. This medication is effective in improving blood sugar control and is utilized for personalized patient treatment.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used in patients who have an allergic reaction to the active ingredient or any of the components. Additionally, it should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, end-stage kidney disease, or those undergoing dialysis should also avoid using this medication. As this medication contains lactose, it should not be given to patients with genetic metabolic disorders such as lactose intolerance or galactose intolerance. In patients with slightly reduced kidney function, it should be administered with caution, and regular monitoring of kidney function before and during administration is important. In patients with heart failure classified as NYHA stage I~II, it should be used cautiously, while it is not recommended for patients in stages III~IV. When used in combination with insulin or insulin secretagogues, there is a risk of hypoglycemia, necessitating dosage adjustments of those medications. While taking this drug, side effects such as hypoglycemia, vulvovaginitis, genital infections, increased urination, urinary tract infections, and fluid volume depletion may occur, so patients should monitor for symptoms. Particularly, elderly patients or those at risk of fluid loss should be cautious of dehydration or hypotension, and it is advisable to regularly observe fluid status. Serious metabolic abnormalities such as ketoacidosis may occur, so if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing develop, immediate consultation with a healthcare professional is necessary. Rare but serious infections such as Fournier's gangrene have also been reported; immediate treatment should be sought if there is pain, swelling, or redness around the perineum or genitals. It is recommended to discontinue the use of this medication if pregnancy occurs or is confirmed, and it should also be avoided during breastfeeding. This medication is not used in children under 18 years old as safety and efficacy have not been established. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment is required depending on the clinical condition. This medication should be kept out of reach of children, and it should not be transferred to other containers. Caution should be exercised while driving or operating machinery, especially when used in combination with insulin or sulfonylureas due to the risk of hypoglycemia. This medication has low interaction potential with other drugs; however, caution is advised when used in conjunction with some diuretics or insulin secretagogues. Diabetic patients should also pay attention to daily foot care and infection prevention while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. Additionally, it is best stored at room temperature between 1°C and 30°C.
Light yellow, biconvex, round film-coated tablet
10 tablets/box [(10 tablets/PTP x 1)], 30 tablets/box [(10 tablets/PTP x 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
JW Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.